In its quarterly letter to investors, David Einhorn’s Greenlight Capital disclosed that its funds returned 25% in the fourth quarter, aided by the fact that “nearly the entire long book performed exceptionally well” in the three month period. New positions established by the funds include Resideo (REZI), NCR Corp. (NCR) and Change Healthcare (CHNG), Greenlight said. In addition, two of the firm’s private investments went public and led to “significant gains,” namely FuboTV (FUBO) and Danimer Scientific (DNMR), On Fubo, Greenlight notes that bears contend that the company won’t be able to compete with bigger players in sports wagering, however he contends that the company’s “integrated opportunity” is “qualitatively different” and thinks a better comparison will be to video gaming companies. In the letter, Greenlight also discussed NeuBase Therapeutics (NBSE), identifying it as an “already-public investment that we have never discussed” in a prior communication. On the short side, Greenlight’s short portfolio “had a difficult quarter,” although the firm “managed to sidestep most of the significant second-half rally” in Tesla (TSLA) as it adjusted its position. Still, short Tesla was the firm’s largest loser in 2020, Greenlight admits. Greenlight also reiterated that it is short Assured Guaranty (AGO) and noted that it has complained in a letter to the SEC about S&P Ratings’ handling of Assured. The firm said “the SEC reached out to us to let us know that the letter appeared very compelling and they would take the matter seriously,” but has since been silent after saying they did not find fraud in the areas about which Greenlight had complained.